Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 May;112(1):37–42. doi: 10.1111/j.1476-5381.1994.tb13025.x

Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

C Thollon 1, C Cambarrat 1, J Vian 1, J F Prost 1, J L Peglion 1, J P Vilaine 1
PMCID: PMC1910295  PMID: 8032660

Abstract

1. S 16257 is a new bradycardic agent. Its electropharmacological profile has been compared to that of the known bradycardic compound UL-FS 49 (Zatebradine). Intracellular recordings of action potentials (APs) were performed with conventional glass microelectrodes. 2. In the rabbit isolated sino-atrial node (SAN) tissue, S 16257 and UL-FS 49 (1 microM, 3 microM and 10 microM) were equipotent in slowing spontaneous APs firing predominantly by decreasing the rate of diastolic depolarization (at 3 microM, -23.8 +/- 3.9% and -27.9 +/- 2.6%, respectively). For the two compounds a maximal effect was obtained at 3 microM. In these preparations, action potential duration at 50% of total repolarization (APD50) was more affected by UL-FS 49 than S 16257 at any concentration tested (at 3 microM, +8.9 +/- 2.9% and +29.1 +/- 3.7% for S 16257 and UL-FS 49, respectively; P < or = 0.01). 3. To estimate the direct effects on AP duration, driven cardiac preparations were exposed to these agents. In guinea-pig papillary muscles, paced at a frequency of 1 Hz, increasing concentrations of S 16257 or UL-FS 49 (0.1 to 10 microM, 30 min exposure for each concentration) slightly prolonged AP repolarization. This prolongation was more marked for UL-FS 49 (at 1 microM, +6.1 +/- 0.6% and +11.2 +/- 1.3% elevation of APD50, for S 16257 and UL-FS 49, respectively). 4. Application of UL-FS 49 (3 microM) to rabbit Purkinje fibres, triggered at a frequency of 0.25 Hz, induced a marked prolongation of APD50 and APD90 (+149.4 +/- 51.2% and +86.0 +/- 15.4%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
37

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsson C., Duker G., Lundberg C., Carlsson L. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res. 1993 May;27(5):861–867. doi: 10.1093/cvr/27.5.861. [DOI] [PubMed] [Google Scholar]
  2. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther. 1985 Mar;232(3):817–825. [PubMed] [Google Scholar]
  3. Damiano B. P., Rosen M. R. Effects of pacing on triggered activity induced by early afterdepolarizations. Circulation. 1984 May;69(5):1013–1025. doi: 10.1161/01.cir.69.5.1013. [DOI] [PubMed] [Google Scholar]
  4. DiFrancesco D. The contribution of the 'pacemaker' current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol. 1991 Mar;434:23–40. doi: 10.1113/jphysiol.1991.sp018457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Doerr T., Trautwein W. On the mechanism of the "specific bradycardic action" of the verapamil derivative UL-FS 49. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):331–340. doi: 10.1007/BF00180659. [DOI] [PubMed] [Google Scholar]
  6. Echt D. S., Berte L. E., Clusin W. T., Samuelsson R. G., Harrison D. C., Mason J. W. Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol. 1982 Nov;50(5):1082–1086. doi: 10.1016/0002-9149(82)90421-0. [DOI] [PubMed] [Google Scholar]
  7. Franke H., Su C. A., Schumacher K., Seiberling M. Clinical pharmacology of two specific bradycardiac agents. Eur Heart J. 1987 Dec;8 (Suppl 50):91–98. doi: 10.1093/eurheartj/8.suppl_l.91. [DOI] [PubMed] [Google Scholar]
  8. Gwilt M., Arrowsmith J. E., Blackburn K. J., Burges R. A., Cross P. E., Dalrymple H. W., Higgins A. J. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther. 1991 Jan;256(1):318–324. [PubMed] [Google Scholar]
  9. Harron D. W., Jady K., Riddell J. G., Shanks R. G. Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol. 1982 Mar-Apr;4(2):213–220. doi: 10.1097/00005344-198203000-00008. [DOI] [PubMed] [Google Scholar]
  10. Indolfi C., Guth B. D., Miura T., Miyazaki S., Schulz R., Ross J., Jr Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation. 1989 Oct;80(4):983–993. doi: 10.1161/01.cir.80.4.983. [DOI] [PubMed] [Google Scholar]
  11. Irisawa H., Brown H. F., Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993 Jan;73(1):197–227. doi: 10.1152/physrev.1993.73.1.197. [DOI] [PubMed] [Google Scholar]
  12. Kern M. J., Deligonul U., Labovitz A. Influence of drug therapy on the ischemic response to acute coronary occlusion in man: supply-side economics. Am Heart J. 1989 Aug;118(2):361–380. doi: 10.1016/0002-8703(89)90198-1. [DOI] [PubMed] [Google Scholar]
  13. Kobinger W., Lillie C. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". Eur J Pharmacol. 1984 Sep 3;104(1-2):9–18. doi: 10.1016/0014-2999(84)90363-7. [DOI] [PubMed] [Google Scholar]
  14. Kobinger W., Lillie C. Specific bradycardic agents--a novel pharmacological class? Eur Heart J. 1987 Dec;8 (Suppl 50):7–15. doi: 10.1093/eurheartj/8.suppl_l.7. [DOI] [PubMed] [Google Scholar]
  15. Krumpl G., Schneider W., Raberger G. Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents? Naunyn Schmiedebergs Arch Pharmacol. 1986 Dec;334(4):540–543. doi: 10.1007/BF00569399. [DOI] [PubMed] [Google Scholar]
  16. Krumpl G., Winkler M., Schneider W., Raberger G. Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs. Br J Pharmacol. 1988 May;94(1):55–64. doi: 10.1111/j.1476-5381.1988.tb11499.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. LAURENT D., BOLENE-WILLIAMS C., WILLIAMS F. L., KATZ L. N. Effects of heart rate on coronary flow and cardiac oxygen consumption. Am J Physiol. 1956 May;185(2):355–364. doi: 10.1152/ajplegacy.1956.185.2.355. [DOI] [PubMed] [Google Scholar]
  18. Li T., Carr A. A., Dage R. C. Effects of MDL 11,939 on action potential and contractile force in cardiac tissues: a comparison with bretylium, clofilium, and sotalol. J Cardiovasc Pharmacol. 1990 Dec;16(6):917–923. doi: 10.1097/00005344-199012000-00009. [DOI] [PubMed] [Google Scholar]
  19. Libersa C., Caron J., Guedon-Moreau L., Adamantidis M., Nisse C. Adverse cardiovascular effects of anti-arrhythmia drugs. Part I: Proarrhythmic effects. Therapie. 1992 May-Jun;47(3):193–198. [PubMed] [Google Scholar]
  20. Lillie C., Kobinger W. Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):791–797. [PubMed] [Google Scholar]
  21. Opie L. H. Pharmacology of acute effort angina. Cardiovasc Drugs Ther. 1989 Jun;3 (Suppl 1):257–270. doi: 10.1007/BF00148470. [DOI] [PubMed] [Google Scholar]
  22. Raberger G., Krumpl G., Schneider W. Effects of the bradycardic agent UL-FS 49 on exercise-induced regional contractile dysfunction in dogs. Int J Cardiol. 1987 Mar;14(3):343–354. doi: 10.1016/0167-5273(87)90205-1. [DOI] [PubMed] [Google Scholar]
  23. Raberger G., Krumpl G., Schneider W., Mayer N. Effects of specific bradycardic agents on exercise-induced regional myocardial dysfunction in dogs. Eur Heart J. 1987 Dec;8 (Suppl 50):53–59. doi: 10.1093/eurheartj/8.suppl_l.53. [DOI] [PubMed] [Google Scholar]
  24. Sonnenblick E. H., Ross J., Jr, Braunwald E. Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol. 1968 Sep;22(3):328–336. doi: 10.1016/0002-9149(68)90117-3. [DOI] [PubMed] [Google Scholar]
  25. Surawicz B. Role of potassium channels in cycle length dependent regulation of action potential duration in mammalian cardiac Purkinje and ventricular muscle fibres. Cardiovasc Res. 1992 Nov;26(11):1021–1029. doi: 10.1093/cvr/26.11.1021. [DOI] [PubMed] [Google Scholar]
  26. Van Bogaert P. P., Goethals M. Blockade of the pacemaker current by intracellular application of UL-FS 49 and UL-AH 99 in sheep cardiac Purkinje fibers. Eur J Pharmacol. 1992 Dec 8;229(1):55–62. doi: 10.1016/0014-2999(92)90285-c. [DOI] [PubMed] [Google Scholar]
  27. Van Bogaert P. P., Goethals M. Pharmacological influence of specific bradycardic agents on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules. Eur Heart J. 1987 Dec;8 (Suppl 50):35–42. doi: 10.1093/eurheartj/8.suppl_l.35. [DOI] [PubMed] [Google Scholar]
  28. Van Bogaert P. P., Goethals M., Simoens C. Use- and frequency-dependent blockade by UL-FS 49 of the if pacemaker current in sheep cardiac Purkinje fibres. Eur J Pharmacol. 1990 Oct 9;187(2):241–256. doi: 10.1016/0014-2999(90)90011-t. [DOI] [PubMed] [Google Scholar]
  29. Wit A. L. Cellular electrophysiologic mechanisms of cardiac arrhythmias. Cardiol Clin. 1990 Aug;8(3):393–409. [PubMed] [Google Scholar]
  30. el-Sherif N., Zeiler R. H., Craelius W., Gough W. B., Henkin R. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Afterdepolarizations and ventricular arrhythmias. Circ Res. 1988 Aug;63(2):286–305. doi: 10.1161/01.res.63.2.286. [DOI] [PubMed] [Google Scholar]
  31. van Woerkens L. J., van der Giessen W. J., Verdouw P. D. The selective bradycardic effects of zatebradine (UL-FS 49) do not adversely affect left ventricular function in conscious pigs with chronic coronary artery occlusion. Cardiovasc Drugs Ther. 1992 Feb;6(1):59–65. doi: 10.1007/BF00050918. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES